Journal ad claims not backed up by references, says study

Share this article:

A small review of drug and device ads in otolaryngology journals found that more than half made claims not supported by the provided reference materials.

The survey of 50 claims made in 23 journal ads from four journals, published in Archives of OtolarygologyHead & Neck Surgery, was conducted by five board-certified otolarygologists. They sorted the claims made into unambiguous clinical outcomes (56%) and vague outcomes (18%). 

The researchers, who found much to disagree on, couldn't reach consensus on 16% of the claims. As for supporting claims, less than half contained some level of research based evidence (48%) while 18% were nonscientific, irrelevant or unreferenced and researchers couldn't reach consensus on 34%. 

Just 10% of claims were deemed unambiguously correct and 6% well supported. References supported associated claims in 34% of the ads while 12% of the claims “actually had references that contradicted part or all of the statement,” the study said. Consensus could not be reached for 52% of the claims reviewed.

While conceding the small scale of the study, the authors said the work “highlights some of the inadequacies in the current state of advertising” and blamed an underfunded FDA for the proliferation of weak or unsupported claims. 

“FDA resources have not increased in proportion to the demands,” they said, adding that “the agency's recent problems have called into question the effectiveness of these allocated resources.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...